Neoleukin-2/15 装甲 CAR-NK 细胞通过 c-Myc/NRF1 激活在实体瘤中维持优越的治疗效果
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.
肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的(招募中)排在最前,共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov、CDE 与 ChiCTR 公开登记。能否入组、费用与可及性,以登记原文和主治医生判断为准。
FOR RESEARCH
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation.
MEMBER ACCOUNT
登录成功会直接打开下一页。